Adamant Health is participating in the International Congress of Parkinson's Disease and Movement Disorders taking place from 27 to 31 August 2023 in Copenhagen, Denmark. Meet us at booth C3-262 to learn more about our data-driven approach!

Adamant Health secures funding from Business Finland's Deep Tech Accelerator program for rapid market entry and targeted growth on international markets. The Deep Tech Accelerator funding will serve as a catalyst in accelerating Adamant Health's entry to selected European markets and drive our growth, particularly within our target customer segments.

Adamant Health’s project focusing on better understanding Parkinson’s disease patients’ lives at home is co-funded by the European Union.

After several successful recruitments during spring 2023, Adamant Health's team has been growing. Meet our team of 14 professionals dedicated to revolutionise the care of Parkinson's disease!

We are participating in the Liikehäiriöpäivät 2023, organised by the Finnish Neurological Society and the Finnish Movement Disorder Society, taking place from 4 - 5 May 2023 in Helsinki, Finland. Meet us at our stand or book a meeting to learn more about our technology and service, and how it can help you making better treatment decisions for your patients and improve their quality of life!

April marks Parkinson’s Awareness Month, an opportunity to increase awareness about the condition and a time to acknowledge the tremendous strength and resilience of people living with the disease and to celebrate the contributions of individuals and organizations supporting efforts to find effective treatments and improve the management Parkinson’s disease.

Adamant Health has opened an office at Hub Panostamo in KPY Novapolis, Kuopio.

Adamant Health participated with its growing team in the UEF Startup Day at the University of Eastern Finland on 19 January 2023.

Are you looking to put your professional expertise to good use by helping people suffering from severe chronic conditions to live a better life? Are you in your element at a fast-growing startup, where you have the opportunity to truly make a change? Do you wish to further develop healthcare systems to serve those in need? If this sounds like you, we’d love to hear from you!

The treatment of Parkinson’s disease is currently based on short doctor’s appointments arranged a few times per year, during which patients talk about their symptoms and the doctor makes observations on the patient. As the symptoms may vary from day to day, prescribing medications based on appointments alone is challenging.

Adamant Health Ltd is a health technology company founded in 2020 and it has its roots in medical physics research at the University of Eastern Finland. The company has developed a new measurement and analysis service to support evaluation of movement disorders, such as the symptoms of Parkinson’s disease and myoclonus-epilepsies. Neurocenter Finland has supported the product development.

Hyvä idea vaatii aina hyvän tiimin ja huippuosaamista. Idean lisäksi tarvitaan joku, joka osaa kaupallistaa idean myytävään muotoon. Adamant Health auttaa ratkaisemaan tämän hetken kriittisiä haasteita liittyen terveyteen, ja on juuri siksi yksi alueemme tulevia tähtiä, kiteyttää Business Kuopion yritysneuvoja Marja-Leena Laitinen.

Adamant Health teams up with German medtech company Gerresheimer to improve the care for people with Parkinson's disease.

Finland and the capital Helsinki, are regarded as Nordic hubs for innovation. The Finnish spirit and advocacy for collaboration is a potent combination – creating new ways of thinking and fresh ideas. EU Startups scoured this high-flying hub to identify early-stage startups with high potential. Adamant Health has been selected as one of the 10 startups to watch in 2022!

Saara Rissanen was awarded the title of docent in the field of medical physics, especially neurophysiological measurements and motion analysis at the University of Eastern Finland. The award reflects Saara’s long academic career and research work especially in using electromyography (EMG) to measure and analyse movement disorders like Parkinson’s disease.

A new study by the University of Eastern Finland and Kuopio University Hospital shows that wearable sensor technology can be used to reliably assess the occurrence of myoclonic jerks in patients with epilepsy also in the home environment. The study was carried out by the New Modalities ecosystem funded by Business Finland, with Adamant Health being one partner focusing on software development.

The Adamant Health analysis module including the analysis algorithms used as part of the Adamant Health Measurement and Analysis Service were CE marked today according to EU MDD. The module is a key part of the service, which can from now on be used for clinical use in addition to research and clinical studies.

Adamant Health Oy kehittää mittaus- ja analyysipalvelua liikehäiriösairauksien oireiden tunnistamiseen, hoidon suunnitteluun ja vaikuttavuuden seurantaan. Hankkeeseen on saatu Euroopan Aluekehitysrahaston (EAKR) tukea ja vastuu viranomaisena toimii Etelä-Savon ELY-keskus.

Tiedeyrittäjyyttä tukemaan tarkoitettu Silmu-apuraha myönnettiin Adamant Health Oy:lle.

15 vuoden tutkimuksen ympärille rakennettu liikeidea jalostui palveluksi. Vuosien varrella ajatus kirkastui. Kuopiolainen tutkija Saara Rissanen päätti ryhtyä yrittäjäksi. "Halusin nähdä, että tekemäni työ tulee ihmisten..